NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury

NCT ID: NCT04474106

Last Updated: 2024-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

246 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-02

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It has been hypothesized that there are two mechanisms of acute traumatic spinal cord injury (SCI): the primary mechanical damage and the secondary injury due to additional pathological processes initiated by the primary injury. Neurological damage due to laceration, contusion, distraction or compression of the spinal cord is called ''primary injury''. This mechanical injury leads to a cascade of biochemical and pathological changes, described as ''secondary injury'', which occurs minutes to weeks after the initial trauma and causes further neurological deterioration. This secondary cascade involves vascular changes, an inflammatory response, neurotoxicity, apoptosis and glial scarring, and further compromises neurological impairment after traumatic spinal cord injury. Edema, ischemia and loss of autoregulation continue to spread bi-directionally from the initial lesion along the spinal cord for up to 72 hours after the trauma.

It has been postulated that the damage caused by the primary injury mechanism is irreversible and therapeutic approaches in recent years have focused on modulating the secondary injury cascade.

Researchers found significantly greater numbers of myelinated fibers in peripheral nerves after a single ESWT application in an experimental model on rats after a homotopic nerve autograft into the sciatic nerve.

In another study a spinal cord ischemia model in mice was performed. ESWT was applied immediately after surgery and the treated animals showed a significantly better motor function and decreased neuronal degeneration compared to the control group within the first 7 days after surgery.

Researchers investigated the effect of low-energy ESWT for the duration of three weeks on a thoracic spinal cord contusion injury model in rats. Animals in the ESWT group demonstrated significantly better locomotor improvement and reduced neuronal loss compared to the control animals at 7, 35, and 42 days after contusion.

It has been postulated previously, that ESWT improves the metabolic activity of various cell types and induces an improved rate of axonal regeneration.

ESWT might be a promising therapeutic strategy in the treatment of traumatic SCI.

The underlying study aims to investigate the effect of ESWT after acute traumatic spinal cord injury in humans within 48 hours of trauma in order to intervene in the secondary injury phase with the objective to reduce the extent of neuronal damage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Traumatic Spinal Cord Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two-arm three-stage adaptive, prospective, multi-center, randomized, double-blind, placebo-controlled clinical trial
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Stratified block randomization with a block size of four and a 1:1 allocation will be used to assign participants to one of two groups (treatment vs. placebo). Three neurological levels of injury will be used for stratification.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESWT

The extracorporeal shockwave therapy is applied once at the level of lesion and 5 segments above and below; or below the occiput (in lesions higher than C6) and above the sacrum (in lesions lower than T12). In addition, the ESWT is applied to the soles of both feet on the medial side of the plantar surface. The ESWT is applied as soon as possible within 48 hours post-injury.

Group Type EXPERIMENTAL

Shock waves

Intervention Type DEVICE

The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.

Control

In the control group, the same procedure is performed, but without the device emitting extracorporeal shock waves using a dummy head.

Group Type SHAM_COMPARATOR

dummy head

Intervention Type DEVICE

The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Shock waves

The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.

Intervention Type DEVICE

dummy head

The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with acute traumatic spinal injuries who are awake, responsive, and oriented at admission
* Patients from the age of 18 years
* Admission to hospital within 24 hours after injury
* Written consent to participate in the study
* Participation in the Austrian Spinal Cord Injury Study (ASCIS)-Registry (only for the Austrian hospitals)

Exclusion Criteria

* Patients who cannot cooperate or are not capable to give consent to participate
* Serious traumatic brain injuries that prevent accurate participation in study procedures and/or adequacy of informed consent Participation in other interventional clinical trials
* Serious concomitant injuries that prevent the neurological initial assessment
* Preexisting neurological conditions that affect the primary endpoint of the study and potentially mask or reduce the therapeutic effect of the ESWT application
* High dose administration of corticosteroids
* Complete spinal cord transection
* Patients with pacemakers or implantable defibrillators
* Patients who are using devices which are sensitive to electromagnetic radiation
* (potential) Pregnancy
* Patients with tumors
* Patients with severe coagulation disorders
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AUVA

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wolfgang Schaden

Deputy Medical Director of Austrian Workers´ Compensation Board (AUVA)

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wolfgang Schaden, Dr.

Role: PRINCIPAL_INVESTIGATOR

AUVA

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University Innsbruck

Innsbruck, Tyrol, Austria

Site Status RECRUITING

Rehazentrum Bad Häring

Bad Häring, , Austria

Site Status ACTIVE_NOT_RECRUITING

Landeskarnkenhaus Feldkirch

Feldkirch, , Austria

Site Status RECRUITING

Unfallkrankenhaus Graz

Graz, , Austria

Site Status RECRUITING

Rehazentrum Tobelbad

Graz, , Austria

Site Status ACTIVE_NOT_RECRUITING

Unfallkrankenhaus Klagenfurt

Klagenfurt, , Austria

Site Status RECRUITING

Rehazentrum Weißer Hof

Klosterneuburg, , Austria

Site Status ACTIVE_NOT_RECRUITING

Unfallkrankenhaus Linz

Linz, , Austria

Site Status RECRUITING

Unfallkrankenhaus Salzburg

Salzburg, , Austria

Site Status RECRUITING

Universitätsklinik für Orthopädie und Traumatologie

Salzburg, , Austria

Site Status WITHDRAWN

Unfallkrankenhaus St. Pölten

Sankt Pölten, , Austria

Site Status WITHDRAWN

Universitätsklinik Wien, AKH

Vienna, , Austria

Site Status RECRUITING

Unfallkrankenhaus Meidling

Vienna, , Austria

Site Status RECRUITING

Unfallkrankenhaus Lorenz Böhler

Vienna, , Austria

Site Status WITHDRAWN

SMZ Ost, Donauspital Abteilung für Unfallchirurgie

Vienna, , Austria

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wolfgang Schaden, Dr

Role: CONTACT

0043 5 9393 20170

Iris Leister, MSc

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Richard Lindtner, Dr

Role: primary

Rene Schmid, Dr.

Role: backup

Rene El-Attal, Prim

Role: primary

Michael Plecko, Prim

Role: primary

Rudolf Pranzl, Prim.

Role: primary

Klaus Katzensteiner, Prim.

Role: primary

Arnold Suda, Prim.

Role: primary

Stefan Hajdu, Prof.

Role: primary

Christian Fialka, Prim.

Role: primary

Medhi Mousavi, Prim

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Leister I, Mittermayr R, Mattiassich G, Aigner L, Haider T, Machegger L, Kindermann H, Grazer-Horacek A, Holfeld J, Schaden W. The effect of extracorporeal shock wave therapy in acute traumatic spinal cord injury on motor and sensory function within 6 months post-injury: a study protocol for a two-arm three-stage adaptive, prospective, multi-center, randomized, blinded, placebo-controlled clinical trial. Trials. 2022 Apr 1;23(1):245. doi: 10.1186/s13063-022-06161-8.

Reference Type DERIVED
PMID: 35365190 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NEUROwave

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treadmill Training for Spinal Cord Injury
NCT00006429 COMPLETED PHASE2
Stem Cells in Spinal Cord Injury
NCT03935724 UNKNOWN PHASE2/PHASE3